Ignite Creation Date:
2025-12-24 @ 6:50 PM
Ignite Modification Date:
2026-07-01 @ 10:05 PM
Study NCT ID:
NCT01142557
Status:
COMPLETED
Last Update Posted:
2014-07-11
First Post:
2010-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization: